Jefferies analyst Peter Welford maintained a Hold rating on Qiagen (QGEN – Research Report) today and set a price target of €42.00. The company’s shares closed yesterday at $35.55.
Welford covers the Healthcare sector, focusing on stocks such as Qiagen, Roche Holding AG, and AstraZeneca. According to TipRanks, Welford has an average return of 7.9% and a 51.88% success rate on recommended stocks.
In addition to Jefferies, Qiagen also received a Hold from Kepler Capital ‘s Maja Pataki in a report issued on October 27. However, on October 20, Bank of America Securities maintained a Buy rating on Qiagen (NYSE: QGEN).
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $51.18 and a one-year low of $34.74. Currently, Qiagen has an average volume of 1.31M.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of QGEN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Qiagen (QGEN) Company Description:
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.
Read More on QGEN:
- QIAGEN exceeds outlook for Q3 2023 with 5% CER sales growth in non-COVID products and adjusted EPS of $0.50 CER
- Qiagen (QGEN) Q3 Earnings Cheat Sheet
- Myriad Genetics, Qiagen enter new master collaboration agreement
- Qiagen, Myriad Genetics partner to advance companion diagnostics development
- Qiagen price target lowered to $50 from $55 at JPMorgan
